Chemical inhibitors of ISLR2 can employ various strategies to disrupt the protein's function in cellular signaling pathways. LY294002 and Wortmannin, both phosphoinositide 3-kinases (PI3K) inhibitors, play a pivotal role in attenuating the PI3K pathway, which is crucial for numerous cellular functions including those linked to ISLR2's role in cell adhesion and signal transduction. Inhibition of PI3K leads to a cascade effect wherein the downstream signaling events that require ISLR2's participation are hampered, resulting in reduced cellular responses mediated by this protein. Similarly, PD98059 and U0126 target the mitogen-activated protein kinase kinase (MEK), which is upstream of extracellular signal-regulated kinase (ERK). By obstructing MEK, the subsequent ERK signaling, which may involve ISLR2, is impaired, limiting the protein's functional contribution to these pathways. SB203580 and SP600125 respectively target p38 MAP kinase and c-Jun N-terminal kinase (JNK), both of which are integral to the cellular stress response and cytokine production. By inhibiting these kinases, the inhibitors can derail the signaling mechanisms that involve ISLR2, thereby diminishing its functional output in cellular stress and inflammatory responses.
In addition to the aforementioned inhibitors, Y-27632, a selective inhibitor of Rho-associated protein kinase (ROCK), influences the cytoskeletal architecture by disrupting actin filament assembly, which is a process potentially regulated by ISLR2. The inhibition of ROCK, therefore, can obstruct the pathways that allow ISLR2 to modulate cell shape and motility. PP2, which inhibits Src family tyrosine kinases, could also impact ISLR2's function since Src kinases are involved in a variety of cellular processes, including those linked to the functionality of ISLR2. The chelation of intracellular calcium by BAPTA-AM can affect ISLR2 by reducing the availability of calcium ions necessary for its function in calcium-dependent signaling processes. LY333531's inhibition of protein kinase C beta (PKCβ) disrupts pathways that regulate cell adhesion and migration where ISLR2 is implicated. ML7's inhibition of myosin light chain kinase (MLCK) affects the cellular contractility and structural integrity, processes in which ISLR2 could be involved. Lastly, NSC 23766 disrupts the action of Rac1, a small GTPase associated with cell adhesion, which is a key process involving ISLR2 in the dynamic regulation of cellular architecture and signal transmission.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3Ks). Given that ISLR2 is implicated in cell adhesion and signal transduction, inhibition of PI3K can alter the downstream signaling required for ISLR2 to mediate its effects on cellular processes, leading to functional inhibition of ISLR2. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is upstream of extracellular signal-regulated kinase (ERK). As ISLR2 is involved in signal transduction, inhibiting MEK and thereby ERK signaling can reduce ISLR2's functional involvement in these pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. By inhibiting p38 MAP kinase, this compound can disrupt signaling pathways that involve ISLR2, leading to a decrease in the functional activities mediated by ISLR2. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). JNK is part of the signaling pathways that regulate various cellular activities. Inhibiting JNK can disrupt the functional role of ISLR2 in these pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. Similar to LY294002, it acts upstream of signaling pathways in which ISLR2 might be involved. By inhibiting PI3K, ISLR2's role in signal transduction can be functionally inhibited. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of Rho-associated protein kinase (ROCK). ISLR2's involvement in cell adhesion and motility suggests it may interact with Rho GTPase signaling. Inhibiting ROCK can thereby impede ISLR2's functional activity related to cell structure and movement. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. Src kinases participate in various signaling cascades, and inhibiting these kinases can hinder ISLR2's function in signal transduction. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK, which, like PD98059, can disrupt the ERK pathway. By inhibiting MEK, U0126 can reduce the functional involvement of ISLR2 in ERK-mediated signal transduction processes. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $449.00 | 61 | |
BAPTA-AM is an intracellular calcium chelator. ISLR2, through its involvement in cell adhesion, may be influenced by calcium-dependent signaling pathways. Chelating calcium can thus inhibit the functional activities of ISLR2 that depend on calcium signaling. | ||||||
LY-333,531 Hydrochloride | 169939-93-9 | sc-364215 sc-364215A | 1 mg 5 mg | $92.00 $281.00 | 6 | |
LY333531 is a selective inhibitor of protein kinase C beta (PKCβ). Since PKCβ is involved in many cellular processes, including those related to adhesion and migration where ISLR2 is implicated, its inhibition can functionally inhibit ISLR2. | ||||||